Core Points - NexGold Mining Corp. has entered into a royalty agreement with Appian Capital Advisory Limited for its Goldboro gold project, receiving US$24 million for a 2.9% net smelter returns royalty on minerals produced until 1,250,000 ounces of gold or equivalent is reached, after which it will only cover gold production [2][5][6] - The company has also signed a non-binding letter of intent for a senior secured credit facility of up to US$175 million from Appian for the development of the Goldboro Gold Project [3][12] Royalty Transaction Details - The royalty agreement includes a US$24 million upfront payment and a 2.9% net smelter returns royalty on all minerals produced until the threshold is met, after which it will only apply to gold [5][6] - The company retains the option to buy back 1.9% of the royalty, subject to certain conditions, and plans to use the proceeds to pay off existing debt and advance the project [6][8] - The transaction is expected to close by the end of September 2025, pending customary closing conditions [11] Project Financing - The non-binding letter of intent with Appian outlines a potential senior secured credit facility of up to US$175 million for the Goldboro Gold Project [3][12] - The completion of the project financing is subject to negotiation and execution of definitive transaction documents and board approvals from both parties [13] Strategic Partnership - The partnership with Appian is seen as a strategic move to secure non-dilutive capital for project advancement and to improve the company's balance sheet [4][6] - Appian has conducted extensive due diligence on the Goldboro Gold Project, indicating confidence in the project's potential [4]

Summary of Royalty Pharma Investor Day Company Overview - **Company**: Royalty Pharma (NasdaqGS:RPRX) - **Industry**: Biopharma royalty market - **Event Date**: September 11, 2025 - **Key Leadership**: George Brofic (Investor Relations), Pablo (CEO), Ashwin (EVP), Chris (EVP), Marshall, Brienne, Terry Core Messages and Financial Performance - **Execution of Strategy**: Royalty Pharma has successfully executed its strategy since its IPO in 2020, delivering strong growth and returns in the rapidly expanding royalty market [21][23][24] - **Market Growth**: The biopharma royalty market has more than doubled in size since 2020, with expectations for continued growth driven by increasing capital needs in the biopharma sector [24][34] - **Financial Targets**: The company is on track to achieve a compounded annual growth rate (CAGR) of 12% in top line revenue since 2020, with a target of at least $4.7 billion by 2030 [26][28][59] - **Capital Deployment**: Royalty Pharma has deployed approximately $14 billion in capital on new royalty transactions since 2020, generating a 15% return on invested capital [26][29] Competitive Advantages - **Business Model**: Royalty Pharma has refined its business model over nearly 30 years, positioning itself as the optimized buyer of royalties, with a focus on delivering win-win solutions for partners [24][39] - **Investment Approach**: The company employs a rigorous investment process, historically transacting on only 2% of initial reviews, and maintains a healthy balance between approved and development stage investments [42][44] - **Risk Mitigation**: Royalty Pharma focuses on low-risk opportunities, with 90% of its royalty investments since 2020 projected to exceed its cost of capital [43][46] Industry Dynamics - **Funding Role of Royalties**: Royalties are increasingly recognized as a critical funding source for biopharma, offering flexibility and non-dilutive capital compared to traditional debt and equity [30][31] - **Market Demand**: The total addressable market for funding in biopharma is projected to exceed $1 trillion over the next decade, driven by high capital needs and the increasing number of licensing deals [34][88] - **Megatrends**: Key trends include rapid scientific innovation, R&D fragmentation, and significant capital requirements in the biopharma sector, all contributing to the growth of the royalty market [82][84][88] Survey Insights - **Deloitte Study**: A recent survey by Deloitte indicates that 87% of biotech executives would consider using royalties for financing, highlighting the growing acceptance and strategic importance of royalties in the capital structure [67][71] - **Executive Perspectives**: The survey revealed that two-thirds of executives cited the lack of equity dilution as a key benefit of royalties, with many expressing increased interest in royalty financing over the past three years [68][71] Philanthropic Efforts - **Community Engagement**: Royalty Pharma emphasizes its commitment to philanthropy and public service, supporting health equity, STEM education, and community initiatives [63][64] Conclusion - **Future Outlook**: Royalty Pharma is positioned for strong value creation, with a best-in-class investment platform and a commitment to delivering mid-teens annualized total shareholder returns over the next five years [60][63]

Portfolio Composition & Growth - Gold Royalty's portfolio has 61% of its book value in Canada and 27% in the USA [20] - Over 90% of the company's value is in gold [19] - The company expects significant growth over the next five years, with attributable gold equivalent ounces (GEOs) projected to increase from 5,462 in 2024 to between 23,000 and 28,000 in 2029 [41] - The company's growth from 2024 to 2025 is projected to be 28%, and its long-term growth outlook to 2029 is 367% [44, 46] Financial Performance & Strategy - Gold Royalty Corp currently has $273 million drawn on its revolving credit facility and $40 million convertible debentures outstanding [55] - The company's 2025 outlook assumes a gold price of $2,668/oz and a copper price of $424/lb [42] - The company's 2029 outlook assumes a gold price of $2,212/oz and a copper price of $423/lb [42] - The company's scalable business model expects recurring cash operating expenses to be $7-8 million per year [50] Asset Highlights - Borborema is expected to have an average production of 83,000 GEO per year in the first three years [117] - REN project is expected to reach full production in 2027 with average yearly production of 140,000 ounces [100, 109] - Côté Gold Project is expected to have a first 6-year average production of 495,000 ounces per year [118]

Core Viewpoint - GENFIT reported a significant increase in cash position and revenues for the first quarter of 2025, driven by a non-dilutive royalty financing agreement and royalties from Iqirvo® sales, indicating a strong financial outlook for the company. Cash Position - As of March 31, 2025, the company's cash and cash equivalents were €129.5 million, up from €74.0 million on March 31, 2024, and €81.8 million on December 31, 2024 [2][3] - The increase in cash is attributed to a €130.0 million first installment from a royalty financing agreement with HCRx, offset by the repurchase of OCEANEs totaling €61.7 million [3] Revenues - Revenues for the first three months of 2025 were €2.8 million, compared to €1.1 million for the same period in 2024, reflecting a substantial growth [4] - The revenue increase is primarily due to royalties from Iqirvo® (elafibranor) sales from Ipsen [4] Corporate Governance Update - Chief Medical Officer Carol Addy will retire effective June 30, 2025, with a replacement to be announced later [6] - CEO Pascal Prigent expressed gratitude for Addy's contributions to the company [6] Company Overview - GENFIT is focused on developing treatments for rare and life-threatening liver diseases, with a strong emphasis on Acute-on-Chronic Liver Failure (ACLF) [7] - The company has a diversified R&D portfolio, including multiple assets under development targeting various liver diseases and related conditions [8][9]